Search

Elizabeth A Mcfaddin

from Nederland, CO
Age ~35
Get Report
Also known as:
Elizabeth Ann Mcfaddin, Elizabeth Mc Faddin
Phone and address:
274 Sky View Dr N, Nederland, CO 80466
Related to:
Gary Mcfaddin, 65Christina Nicole Mcfaddin, 34Michelle L Mclain, 45Timothy R Mcmanus, 68Jeffrey W Mcfaddin, 31Joanne Mcfaddin, 87Karen R Mckissick, 77Claudia K Mcintosh, 77Michael S Mckissick, 78Charles W Mcfaddin, 88Jonathan D Rich, 39Susan E Mcfaddin, 64
Connected to:
Adam Mcfaddin, 40Amy S Mcfaddin, 47Richard K Mcfaddin, 60Traci L Mcfaddin, 58Deeandria V Mcfadgon, 38Ashley W Mcfadin, 36Kelli M Mcfadin, 58Abby E Mcfadyen, 36Billy H Mcfadyen, 90Catherine H Mcfadyen, 104

Elizabeth Mcfaddin Phones & Addresses

  • 274 Sky View Dr N, Nederland, CO 80466
  • Lafayette, CO
  • Fort Collins, CO
  • Thornton, CO
  • Boulder, CO
  • 609 Rawlins Way, Lafayette, CO 80026

Publications

Us Patents

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20230090520, Mar 23, 2023
Filed:
Nov 19, 2021
Appl. No.:
17/530702
Inventors:
- Boulder CO, US
Sean ARONOW - Boulder CO, US
James F. BLAKE - Boulder CO, US
Barbara J. BRANDHUBER - Boulder CO, US
Adam COOK - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Boulder CO, US
Elizabeth A. MCFADDIN - Boulder CO, US
Megan L. MCKENNEY - Boulder CO, US
Oren T. MCNULTY - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Tony P. TANG - Boulder CO, US
Li REN - Boulder CO, US
International Classification:
A61K 31/496
C07D 471/04
A61P 1/12
A61P 35/04
C07D 519/00
A61P 35/02
A61P 35/00
A61K 31/444
A61K 31/4985
A61K 31/4995
A61K 31/506
A61K 31/5377
A61K 45/06
A61K 31/551
Abstract:
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Compounds Useful For Inhibiting Ret Kinase

View page
US Patent:
20210363140, Nov 25, 2021
Filed:
Apr 23, 2021
Appl. No.:
17/238370
Inventors:
- Indianapolis IN, US
Steven W. ANDREWS - Longmont CO, US
Kevin R. CONDROSKI - Lafayette CO, US
Thomas C. IRVIN - Erie CO, US
Gabrielle R. KOLAKOWSKI - Longmont CO, US
Manoj KUMAR - Longmont CO, US
Elizabeth A. MCFADDIN - Nederland CO, US
Megan MCKENNEY - Boulder CO, US
Michael J. MUNCHHOF - Corvallis MT, US
Michael B. WELCH - Westminster CO, US
International Classification:
C07D 413/14
C07D 413/12
C07D 231/38
C07D 417/12
Abstract:
Provided herein are RET kinase inhibitors according to the formula:pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R, n, X, X, X, X, and Rhave the meanings given in the specification.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20200383966, Dec 10, 2020
Filed:
Sep 23, 2019
Appl. No.:
16/579150
Inventors:
- Boulder CO, US
Sean ARONOW - Boulder CO, US
James F. BLAKE - Boulder CO, US
Barbara J. BRANDHUBER - Boulder CO, US
James COLLIER - Boulder CO, US
Adam COOK - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Boulder CO, US
Elizabeth A. McFADDIN - Boulder CO, US
Megan L. McKENNEY - Boulder CO, US
Oren T. McNULTY - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Ginelle A. RAMANN - Boulder CO, US
Tony P. TANG - Boulder CO, US
Li REN - Boulder CO, US
Shane M. WALLS - Boulder CO, US
International Classification:
A61K 31/4545
A61K 31/4162
C07D 471/04
A61P 1/00
A61P 35/00
A61P 35/02
A61K 31/444
A61K 31/497
A61K 31/501
A61K 31/506
A61K 31/5377
A61K 45/06
A61P 1/12
Abstract:
Provided herein are compounds of the Formula I:or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted Pyrazolyl[4,3-C]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20200339579, Oct 29, 2020
Filed:
Jan 18, 2019
Appl. No.:
16/962305
Inventors:
- Boulder CO, US
LI REN - Boulder CO, US
Ginelle A. RAMANN - Boulder CO, US
David A. MORENO - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
Elizabeth A. MCFADDIN - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Longmont CO, US
James F. BLAKE - Boulder CO, US
Donghua DAI - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Dean KAHN - Boulder CO, US
International Classification:
C07D 471/04
C07F 9/6561
Abstract:
Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R, Rand Rhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted Pyrrolo[2,3-D]Pyrimidines Compounds As Ret Kinase Inhibitors

View page
US Patent:
20200339589, Oct 29, 2020
Filed:
Jan 18, 2019
Appl. No.:
16/962345
Inventors:
- Boulder CO, US
Donghua DAI - Boulder CO, US
Julia HAAS - Boulder CO, US
Yutong JIANG - Boulder CO, US
Gabrielle R. KOLAKOWSKI - Longmont CO, US
Elizabeth A. MCFADDIN - Nederland CO, US
Megan L. MCKENNEY - Boulder CO, US
Andrew T. METCALF - Boulder CO, US
David A. MORENO - Boulder CO, US
Brett PRIGARO - Boulder CO, US
Ginelle A. RAMANN - Boulder CO, US
Li REN - Boulder CO, US
International Classification:
C07D 487/04
Abstract:
Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Crystalline Forms

View page
US Patent:
20190263811, Aug 29, 2019
Filed:
Oct 10, 2018
Appl. No.:
16/156880
Inventors:
- Boulder CO, US
David Fry - Boulder CO, US
Elizabeth A. McFaddin - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Julia Haas - Boulder CO, US
Tony P. Tang - Boulder CO, US
Yutong Jiang - Boulder CO, US
International Classification:
C07D 471/08
A61K 9/00
A61P 35/00
Abstract:
Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula III), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-hydroxy-4-(pyridin-2-ylmethyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula IV), and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, the application relates to novel crystalline forms of Formula I-IV and pharmaceutically acceptable salts thereof useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20190183886, Jun 20, 2019
Filed:
Oct 29, 2018
Appl. No.:
16/173100
Inventors:
- Boulder CO, US
Sean Aronow - Boulder CO, US
James F. Blake - Boulder CO, US
Barbara J. Brandhuber - Boulder CO, US
Adam Cook - Boulder CO, US
Julia Haas - Boulder CO, US
Yutong Jiang - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Elizabeth A. McFaddin - Boulder CO, US
Megan L. McKenney - Boulder CO, US
Oren T. McNulty - Boulder CO, US
Andrew T. Metcalf - Boulder CO, US
David A. Moreno - Boulder CO, US
Tony P. Tang - Boulder CO, US
Li Ren - Boulder CO, US
International Classification:
A61K 31/496
C07D 471/04
A61K 31/551
A61K 31/4985
A61P 35/00
A61K 31/444
A61K 45/06
A61P 1/12
A61K 31/506
A61K 31/5377
A61P 35/02
C07D 519/00
A61P 35/04
A61K 31/4995
Abstract:
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

View page
US Patent:
20180148445, May 31, 2018
Filed:
Dec 29, 2017
Appl. No.:
15/858929
Inventors:
- Boulder CO, US
Sean Aronow - Boulder CO, US
James F. Blake - Boulder CO, US
Barbara J. Brandhuber - Boulder CO, US
James Collier - Boulder CO, US
Adam Cook - Boulder CO, US
Julia Haas - Boulder CO, US
Yutong Jiang - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Elizabeth A. McFaddin - Boulder CO, US
Megan L. McKenney - Boulder CO, US
Oren T. McNulty - Boulder CO, US
Andrew T. Metcalf - Boulder CO, US
David A. Moreno - Boulder CO, US
Ginelle A. Ramann - Boulder CO, US
Tony P. Tang - Boulder CO, US
Li Ren - Boulder CO, US
Shane M. Walls - Boulder CO, US
International Classification:
C07D 471/04
A61P 35/00
A61P 1/00
Abstract:
Provided herein are compounds of the Formula I:or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Control profile
Elizabeth A Mcfaddin from Nederland, CO, age ~35 Get Report